Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensovibep versus placebo in ambulatory adults with symptomatic COVID-19
NL-OMON51156Phase 2Active, not recruiting
- Sponsor
- Molecular Partners AG
- Start
- Jul 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ensovibep in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Molecular Partners AG. Primary endpoints: Time-weighted change from baseline in viral load through Day 8 and Hospitalization, emergency room visit, or death through Day 29. Started Jul 2021; status: active, not recruiting.
02
Drugs
ensovibep
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51156.